State Street’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-226,658
| Closed | -$4.17M | – | 4005 |
|
|
2020
Q4 | $4.17M | Sell |
226,658
-1,412
| -0.6% | -$25.7K | ﹤0.01% | 3052 |
|
|
2020
Q3 | $4.18M | Buy |
228,070
+3,752
| +2% | +$63.1K | ﹤0.01% | 2867 |
|
|
2020
Q2 | $3.36M | Buy |
224,318
+6,588
| +3% | +$94.1K | ﹤0.01% | 2958 |
|
|
2020
Q1 | $3.44M | Sell |
217,730
-11,236
| -5% | -$182K | ﹤0.01% | 2810 |
|
|
2019
Q4 | $3.72M | Buy |
228,966
+10,750
| +5% | +$179K | ﹤0.01% | 2988 |
|
|
2019
Q3 | $3.24M | Buy |
218,216
+5,153
| +2% | +$69.5K | ﹤0.01% | 3010 |
|
|
2019
Q2 | $3.52M | Buy |
213,063
+35,165
| +20% | +$574K | ﹤0.01% | 3002 |
|
|
2019
Q1 | $3.08M | Buy |
177,898
+6,184
| +4% | +$112K | ﹤0.01% | 2980 |
|
|
2018
Q4 | $3.03M | Buy |
171,714
+1,032
| +0.6% | +$17.5K | ﹤0.01% | 2944 |
|
|
2018
Q3 | $3.1M | Buy |
170,682
+29,018
| +20% | +$595K | ﹤0.01% | 3081 |
|
|
2018
Q2 | $2.77M | Buy |
141,664
+130,335
| +1,150% | +$2.44M | ﹤0.01% | 3127 |
|
|
2018
Q1 | $199K | Buy |
+11,329
| New | +$207K | ﹤0.01% | 3559 |
|
|
2017
Q2 | – | Sell |
-128,469
| Closed | -$1.51M | – | 3760 |
|
|
2017
Q1 | $1.51M | Buy |
128,469
+1,256
| +1% | +$15.3K | ﹤0.01% | 3182 |
|
|
2016
Q4 | $1.67M | Buy |
127,213
+8,328
| +7% | +$111K | ﹤0.01% | 3160 |
|
|
2016
Q3 | $1.72M | Buy |
118,885
+3,976
| +3% | +$56.4K | ﹤0.01% | 3029 |
|
|
2016
Q2 | $1.38M | Sell |
114,909
-2,229
| -2% | -$35.8K | ﹤0.01% | 3177 |
|
|
2016
Q1 | $2.19M | Buy |
117,138
+16,032
| +16% | +$266K | ﹤0.01% | 2974 |
|
|
2015
Q4 | $2.17M | Buy |
101,106
+11,340
| +13% | +$240K | ﹤0.01% | 2968 |
|
|
2015
Q3 | $1.52M | Buy |
89,766
+43,814
| +95% | +$1.09M | ﹤0.01% | 3099 |
|
|
2015
Q2 | $1.73M | Buy |
+45,952
| New | +$1.48M | ﹤0.01% | 3112 |
|
State Street's CBMG Position: Q1 2021 in Review
State Street sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 226,658 shares — an estimated $4.17M sold.
State Street first reported a position in CBMG in Q2 2015 and held it in 20 quarters. The position peaked at $4.18M in Q3 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- State Street reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- State Street sold 226,658 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $4.17M.
- State Street first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 20 quarters.
- State Street's Cellular Biomedicine Group, Inc. position peaked at $4.18M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on State Street's 13F filing for Q1 2021, filed 17 May 2021.